Medrad, Inc. v. Tyco Healthcare Group Lp

466 F.3d 1047, 80 U.S.P.Q. 2d (BNA) 1526, 2006 U.S. App. LEXIS 25673, 2006 WL 2942706
CourtCourt of Appeals for the Federal Circuit
DecidedOctober 16, 2006
Docket2006-1082
StatusPublished
Cited by10 cases

This text of 466 F.3d 1047 (Medrad, Inc. v. Tyco Healthcare Group Lp) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Medrad, Inc. v. Tyco Healthcare Group Lp, 466 F.3d 1047, 80 U.S.P.Q. 2d (BNA) 1526, 2006 U.S. App. LEXIS 25673, 2006 WL 2942706 (Fed. Cir. 2006).

Opinion

*1049 LINN, Circuit Judge.

Medrad, Inc. appeals from a final judgment granting the motion of Tyco Healthcare Group LP, Mallinckrodt Inc., Liebel-Flarsheim Co., and Nemoto Kyorindo Co., Ltd. (collectively “Tyco”) for summary judgment of invalidity of U.S. Reissue Patent No. 37,602 (’602 reissue patent). Medrad, Inc. v. Tyco Healthcare Growp, LP, 391 F.Supp.2d 374 (W.D.Pa.2005). Because we conclude that the defect that formed the basis for the '602 reissue patent was within the plain meaning of 35 U.S.C. § 251, we reverse and remand.

I. BACKGROUND

The '602 reissue patent relates to patient infusion systems for use with magnetic resonance imaging systems. There are two predecessor patents to the '602 reissue patent, both of which were assigned to Medrad. The first predecessor patent was U.S. Patent No. 5,494,036 (’036 patent), which issued on February 27, 1996. On February 23, 1998, Medrad filed an application for reissue of the '036 patent and submitted reissue declarations stating that the inventors had claimed less than they had a right to claim (an “under-claiming” error). During prosecution of the reissue, Medrad narrowed the scope of various claims (correcting an “overclaiming” error) and corrected inventorship in addition to correcting the underclaiming error. Medrad did not submit supplemental reissue declarations regarding the over-claiming or inventorship errors as required by 37 C.F.R. § 1.175. That reissue application issued as U.S. Reissue Patent No. 36,648 (’648 reissue patent) and is the second predecessor patent to the '602 reissue patent.

On April 25, 2000, Medrad filed a complaint with the U.S. International Trade Commission alleging illegal importation of devices that infringed the '648 reissue patent. On motion for summary judgment, the administrative law judge (“ALJ”) initially found that the '648 reissue patent was invalid due to Medrad’s failure to file supplemental reissue declarations regarding the overclaiming and inventorship errors that were ultimately corrected during prosecution. The ALJ’s initial decision became the final determination of the International Trade Commission, and the investigation was terminated.

Before the ALJ’s initial determination became final, Medrad filed an application for reissue of the '648 reissue patent seeking to correct its failure to submit supplemental declarations during prosecution of the '648 reissue patent. That application resulted in the '602 reissue patent, which is the subject of this appeal. The '602 reissue patent and the '648 reissue patent have identical specifications, drawings, and claims; the only difference is that Medrad filed supplemental declarations during prosecution of the '602 reissue patent that allegedly corrected the failure to do so during prosecution of the '648 reissue patent.

On October 24, 2001, Medrad filed a complaint in district court against Tyco alleging infringement of the '602 reissue patent. Medrad and Tyco filed cross motions for summary judgment regarding the validity of the '602 reissue patent. Medrad, 391 F.Supp.2d at 376. Tyco argued that the reissue was defective under 35 U.S.C. § 251 because it did not correct one of four statutorily identified errors: a defect in the specification, a defect in the drawings, or an error in either claiming too much or too little in the patent. Id. The court construed section 251 as requiring “that some error in the specification, drawings, or claim of the patent be corrected as a result of the reissue process.” Id. at 378. Because the error that Medrad corrected was “procedural” and not an er *1050 ror in the specification, drawings, or claims of the '648 reissue patent, the court granted Tyco’s motion, denied Medrad’s motion, dismissed all other pending motions as moot, and entered final judgment holding the '602 reissue patent invalid. Id. at 382-83.

On appeal, Medrad challenges the district court’s interpretation of 35 U.S.C. § 251 and its invalidity finding based on that interpretation. We have jurisdiction pursuant to 28 U.S.C. § 1295(a)(1).

II. DISCUSSION

A. Standard of Review

We review a district court’s grant of summary judgment of invalidity de novo. Baxter Int’l, Inc. v. COBE Labs., Inc., 88 F.3d 1054, 1058 (Fed.Cir.1996). Summary judgment is proper only if there are no genuine issues of material fact and the movant is entitled to judgment as a matter of law. See Fed.R.Civ.P. 56(e); Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 250, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986). The scope of 35 U.S.C. § 251 is a question of statutory construction that we review without deference. NTP, Inc. v. Research In Motion, Ltd., 418 F.3d 1282, 1314 (Fed.Cir.2005). “Whether the statutory requirement of ‘error’ [in section 251] has been met is an issue of law which we review de novo.” Mentor Corp. v. Coloplast, Inc., 998 F.2d 992, 994 (Fed.Cir.1993).

B. Analysis

Medrad argues that the district court erred in concluding that 35 U.S.C. § 251 does not extend to reissues based on defects in inventor declarations. Specifically, Medrad argues that section 251 does not require there to be an error in the specification, drawings, or claims of the patent, but rather encompasses any inadvertent error that results in underclaiming or overclaiming. Medrad cites In re Bennett, 766 F.2d 524 (Fed.Cir.1985), Brenner v. State of Israel, 400 F.2d 789 (D.C.Cir.1968), Fontijn v. Okamoto, 518 F.2d 610 (C.C.P.A.1975), and A.F. Stoddard & Co. v. Dann, 564 F.2d 556

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Zimmer Surgical, Inc. v. Stryker Corp.
365 F. Supp. 3d 466 (D. Delaware, 2019)
Inre: Dinsmore
757 F.3d 1343 (Federal Circuit, 2014)
Disney Enterprises, Inc. v. Rea
940 F. Supp. 2d 288 (E.D. Virginia, 2013)
Emtel, Inc. v. Lipidlabs, Inc.
583 F. Supp. 2d 811 (S.D. Texas, 2008)
LG Electronics, Inc. v. Quanta Computer Inc.
566 F. Supp. 2d 910 (W.D. Wisconsin, 2008)
Kavanaugh v. Peake
273 F. App'x 937 (Federal Circuit, 2008)
Chambers v. Department of the Interior
515 F.3d 1362 (Federal Circuit, 2008)
Cargill, Inc. v. Canbra Foods, Ltd.
476 F.3d 1359 (Federal Circuit, 2007)
LUCENT TECHNOLOGIES INC. v. Gateway, Inc.
470 F. Supp. 2d 1163 (S.D. California, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
466 F.3d 1047, 80 U.S.P.Q. 2d (BNA) 1526, 2006 U.S. App. LEXIS 25673, 2006 WL 2942706, Counsel Stack Legal Research, https://law.counselstack.com/opinion/medrad-inc-v-tyco-healthcare-group-lp-cafc-2006.